MACK RSI Chart
Last 7 days
0.3%
Last 30 days
3.3%
Last 90 days
3.1%
Trailing 12 Months
18.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2019 | 0 | 2.8M | 3.8M | 4.9M |
2017 | 0 | 96.7M | 49.2M | 1.7M |
2016 | 95.7M | 92.8M | 104.5M | 144.3M |
2015 | 104.6M | 113.3M | 101.7M | 89.3M |
2014 | 46.2M | 55.5M | 76.7M | 102.8M |
2013 | 52.2M | 58.6M | 54.2M | 47.8M |
2012 | 39.1M | 44.6M | 47.3M | 48.9M |
2011 | 23.8M | 27.3M | 30.7M | 34.2M |
2010 | 0 | 0 | 0 | 20.3M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 28, 2023 | andersen eric | bought | 11,441 | 13.3503 | 857 | - |
Dec 26, 2023 | andersen eric | bought | 640,313 | 13.15 | 48,693 | - |
Dec 07, 2023 | andersen eric | bought | 1,298,470 | 12.8498 | 101,050 | - |
Nov 17, 2023 | andersen eric | bought | 3,750 | 12.5 | 300 | - |
Nov 14, 2023 | andersen eric | bought | 627,125 | 12.5 | 50,170 | - |
Nov 13, 2023 | andersen eric | bought | 192,875 | 12.3876 | 15,570 | - |
Nov 10, 2023 | andersen eric | bought | 469,008 | 12.3222 | 38,062 | - |
Nov 09, 2023 | andersen eric | bought | 121,618 | 12.1923 | 9,975 | - |
Nov 08, 2023 | andersen eric | bought | 167,701 | 12.132 | 13,823 | - |
Aug 11, 2023 | crocker gary l | bought | 24,865 | 12.4326 | 2,000 | see remarks |
Which funds bought or sold MACK recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | COMERICA BANK | unchanged | - | 680 | 7,385 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 164,301 | 164,301 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.89 | -7,552 | 15,553 | -% |
May 15, 2024 | Madison Avenue Partners, LP | reduced | -29.99 | -1,697,620 | 5,719,250 | 0.92% |
May 15, 2024 | Western Standard LLC | unchanged | - | 2,954,620 | 32,088,000 | 15.37% |
May 15, 2024 | Indaba Capital Management, L.P. | sold off | -100 | -2,996,580 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -77.88 | -12,841 | 4,136 | -% |
May 15, 2024 | Newtyn Management, LLC | unchanged | - | 2,548,220 | 27,674,500 | 5.51% |
May 15, 2024 | Aristides Capital LLC | new | - | 147,700 | 147,700 | 0.05% |
May 15, 2024 | Schonfeld Strategic Advisors LLC | new | - | 159,516 | 159,516 | -% |
Unveiling Merrimack Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Merrimack Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Merrimack Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2019Q4 | 2019Q3 | 2019Q2 | 2017Q4 | 2017Q3 | 2017Q2 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 | 2015Q1 | 2014Q4 | 2014Q3 | 2014Q2 | 2014Q1 | 2013Q4 | 2013Q3 | 2013Q2 |
Revenue | - | - | - | 1.00 | - | 20.00 | 41.00 | 61.00 | 28.00 | 34.00 | 21.00 | 21.00 | 16.00 | 37.00 | 15.00 | 34.00 | 28.00 | 28.00 | 13.00 | 8.00 | 7.00 | 18.00 |
Cost Of Revenue | - | - | - | - | - | - | - | 3.00 | 1.00 | 2.00 | 1.00 | 0.00 | - | - | - | - | - | - | - | - | - | - |
Costs and Expenses | - | - | - | - | 17.00 | 17.00 | 35.00 | 42.00 | 36.00 | 36.00 | 34.00 | -9.63 | 55.00 | 55.00 | 45.00 | 39.00 | 52.00 | 42.00 | 37.00 | 36.00 | 43.00 | 48.00 |
Operating Expenses | 161.3% | 2.00 | 1.00 | 9.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
S&GA Expenses | -49.1% | 2.00 | 4.00 | 6.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
R&D Expenses | - | - | - | 5.00 | 12.00 | 14.00 | 20.00 | 26.00 | 28.00 | 28.00 | 28.00 | 38.00 | 30.00 | 26.00 | 26.00 | 31.00 | 44.00 | 34.00 | 30.00 | - | - | - |
Interest Expenses | - | 0.00 | - | 1.00 | 4.00 | 2.00 | 27.00 | 2.00 | 2.00 | 16.00 | 3.00 | 5.00 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 4.00 | - | - |
Income Taxes | - | - | - | - | -10.03 | -2.13 | -30.24 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | -Infinity% | -2.15 | - | - | -21.86 | -7.46 | -59.88 | -43.54 | -36.61 | -51.63 | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 562.6% | 3.00 | -0.70 | -9.43 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 1173.3% | 244 | 19.00 | 19.00 | 19.00 | 20.00 | 20.00 | 14.00 | 14.00 | 15.00 | 15.00 | 15.00 | 16.00 | 16.00 | 17.00 | 19.00 | 20.00 | 21.00 | 20.00 | 25.00 | 45.00 | 74.00 |
Current Assets | 1173.6% | 244 | 19.00 | 19.00 | 19.00 | 20.00 | 20.00 | 14.00 | 14.00 | 15.00 | 15.00 | 15.00 | 16.00 | 16.00 | 17.00 | 19.00 | 19.00 | 20.00 | 19.00 | 22.00 | 43.00 | 64.00 |
Cash Equivalents | 3809.8% | 234 | 6.00 | 6.00 | 10.00 | 19.00 | 19.00 | 13.00 | 13.00 | 14.00 | 14.00 | 15.00 | 15.00 | 14.00 | 14.00 | 16.00 | 16.00 | 18.00 | 17.00 | 21.00 | 37.00 | 37.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00 |
Liabilities | 95.7% | 23.00 | 12.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 3.00 | 3.00 | 5.00 | 5.00 | 25.00 |
Current Liabilities | 5041.0% | 23.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 3.00 | 3.00 | 5.00 | 5.00 | 12.00 |
Shareholder's Equity | 1082.3% | 222 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 13.00 | 14.00 | 14.00 | 14.00 | 15.00 | 15.00 | 16.00 | 16.00 | 17.00 | 17.00 | 18.00 | 17.00 | 20.00 | 40.00 | 49.00 |
Retained Earnings | 36.7% | -347 | -548 | -548 | -548 | -547 | -547 | -547 | -546 | -546 | -546 | -545 | -545 | -544 | -543 | -542 | -541 | -540 | -540 | -543 | -543 | -533 |
Additional Paid-In Capital | 0.3% | 568 | 566 | 566 | 566 | 566 | 566 | 559 | 559 | 559 | 559 | 559 | 559 | 559 | 558 | 558 | 558 | 557 | 557 | 563 | 582 | 581 |
Shares Outstanding | 1.3% | 15.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 130 | - | - | - | 130 | - | - | - | 68.00 | - | - | - | 44.00 | - | - | - | 79.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 29.8% | -226 | -322 | -176 | -624 | -400 | -185 | -264 | -939 | -354 | -355 | -445 | 1,019 | -437 | -1,776 | 135 | -1,979 | -1,005 | -2,640 | -3,203 | -11,873 | -13,652 |
Cashflow From Investing | 335194.1% | 228,000 | 68.00 | -3,845 | -8,811 | 139 | - | - | - | 445 | - | 94.00 | - | 50.00 | - | - | -311 | 2,450 | 5,000 | 6,500 | 28,210 | 30,115 |
Cashflow From Financing | 1016.5% | 1,485 | 133 | - | 209 | 179 | - | - | - | - | - | - | - | 239 | - | - | - | - | -6,638 | -19,940 | - | - |
Dividend Payments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6,700 | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
General and administrative expenses | $ 669 | $ 586 |
Gain on sale of in-process research and development | (139) | |
Total operating expenses | 669 | 447 |
Loss from operations | (669) | (447) |
Other income: | ||
Interest income | 233 | 176 |
Total other income | 233 | 176 |
Net loss from continuing operations | (436) | (271) |
Discontinued operations: | ||
Income from discontinued operations, net of tax | 201,806 | |
Net income and comprehensive income | $ 201,370 | $ (271) |
Basic and dilutive net income (loss) per common share | ||
Net loss from continuing operations - basic | $ (0.03) | $ (0.02) |
Net loss from continuing operations - diluted | (0.03) | (0.02) |
Net income from discontinued operations, net of tax - basic | 13.96 | |
Net income from discontinued operations, net of tax - diluted | 13.96 | |
Net income (loss) per common share - basic | 13.93 | (0.02) |
Net income (loss) per common share - diluted | $ 13.93 | $ (0.02) |
Weighted-average common shares used to compute basic net income (loss) per common share | 14,452 | 14,252 |
Weighted-average common shares used to compute diluted net income (loss) per common share | 14,452 | 14,252 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 234,160 | $ 5,989 |
Short-term investments | 9,950 | 12,886 |
Prepaid expenses and other current assets | 209 | 309 |
Total current assets | 244,319 | 19,184 |
Other assets | 3 | 4 |
Total assets | 244,322 | 19,188 |
Current liabilities: | ||
Accounts payable, accrued expenses and other | 566 | 441 |
Income taxes payable | 22,106 | |
Total current liabilities | 22,672 | 441 |
Total liabilities | 22,672 | 441 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.01 par value: 10,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 or December 31, 2023 | ||
Common stock, $0.01 par value: 30,000 shares authorized at March 31, 2024 and December 31, 2023; 14,532 and 14,351 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 1,345 | 1,343 |
Additional paid-in capital | 567,752 | 566,221 |
Accumulated deficit | (347,447) | (548,817) |
Total stockholders’ equity | 221,650 | 18,747 |
Total liabilities and stockholders’ equity | $ 244,322 | $ 19,188 |